Angiodynamics INC

AngioDynamics announced record fiscal year 2026 results, driven by strong double-digit growth in its Med Tech segment, achieving full-year profitability and ending the year with a debt-free balance sheet.

AngioDynamics has initiated patent infringement litigation against Endovascular Engineering, Inc. regarding its thrombectomy technology.

AngioDynamics, Inc. announced the planned retirement of CEO James C. Clemmer by November 2026 and approved retention agreements for its executive leadership team to ensure a smooth transition.

AngioDynamics, Inc. presented an updated financial outlook and showcased its MedTech portfolio's strong performance and innovation at the J.P. Morgan 44th Annual Healthcare Conference.

AngioDynamics announced robust fiscal Q2 2026 results driven by double-digit Med Tech growth, increased profitability, and raised full-year guidance.

AngioDynamics, Inc. announced the successful election of Class I directors, ratification of its independent auditor, and advisory approval of executive compensation at its Annual Meeting of Shareholders on November 10, 2025.

AngioDynamics reported a net loss of $8.1 million on $78.4 million in revenue for the third quarter of fiscal year 2026, driven by strong Med Tech segment growth.

AngioDynamics reports increased Q2 2026 net sales and improved gross margin, significantly reducing its net loss compared to the prior year.

AngioDynamics reports a 12.2% increase in net sales to $75.7 million and a reduced net loss of $10.9 million for the first quarter of fiscal year 2026, driven by strong Med Tech performance.

AngioDynamics' Q3 2025 results show a decrease in overall revenue due to divestitures, but growth in the Med Tech segment partially offset the decline.

AngioDynamics' Q2 2025 results show a decrease in revenue due to divestitures, but an increase in gross profit margin and a reduction in net loss.

AngioDynamics experienced a net loss in the first quarter of fiscal year 2025, primarily due to strategic divestitures and product line discontinuations, despite growth in its Med Tech segment.

AngioDynamics, Inc. announced its fiscal year 2026 results, highlighting a 9.5% increase in net sales driven by its Med Tech segment, while navigating a net loss and implementing strategic restructuring initiatives.

AngioDynamics, a medical technology company, reported a significant reduction in net loss and an increase in gross margin for fiscal year 2025, driven by strong growth in its Med Tech segment and strategic divestitures, despite an overall revenue decline.

AngioDynamics' 2024 annual report highlights a strategic shift towards outsourcing manufacturing and focusing on high-growth Med Tech products, alongside significant financial impacts from divestitures and restructuring.

Warren Nighan Jr, SVP Quality and Regulatory of Angiodynamics Inc, sold 23,370 shares of common stock on July 30, 2026 for $14.72 per share.

Laura Piccinini, SVP International of Angiodynamics Inc, reported multiple transactions in common stock on July 22, 2026.

Warren Nighan Jr, SVP Quality and Regulatory of Angiodynamics Inc, reported multiple transactions in common stock on July 22, 2026.

Stephen A Trowbridge, EVP and CFO of Angiodynamics Inc, reported multiple transactions in common stock on July 22, 2026.

James C Clemmer, President and CEO and a Director of Angiodynamics Inc, reported multiple transactions in common stock on July 22, 2026.

Chad Thomas Campbell, SVP/GM, Vascular Access of Angiodynamics Inc, reported multiple transactions in common stock on July 22, 2026.

AngioDynamics, Inc. filed a definitive proxy statement (DEFA14A) with the U.S. Securities and Exchange Commission.

AngioDynamics, Inc. announced its 2025 Annual Meeting agenda, including director elections and executive compensation votes, alongside fiscal year 2025 performance highlights showing strategic transformation progress.

AngioDynamics, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission (SEC) pursuant to Section 14(a) of the Securities Exchange Act of 1934.

AngioDynamics is asking shareholders to approve an amendment to its 2020 Equity Incentive Plan to increase the number of shares available for issuance.

The Vanguard Group has filed an amendment to its Schedule 13G for AngioDynamics Inc., reporting 0% beneficial ownership due to an internal corporate realignment.

Divisadero Street Capital Management and related entities filed an amendment to their Schedule 13G, disclosing a passive beneficial ownership of 0.01% in AngioDynamics, Inc. common stock as of December 31, 2025.

Systematic Financial Management LP has disclosed a 6.05% beneficial ownership stake in AngioDynamics Inc., signaling increased institutional interest.

Kevin Kotler has reported a 5.9% beneficial ownership stake in AngioDynamics, Inc., holding 2,421,526 shares of common stock.

Millennium Management LLC and affiliated entities have filed an amended Schedule 13G, disclosing their passive beneficial ownership of AngioDynamics, Inc. common stock as of December 31, 2025.

Point72 Asset Management, along with its affiliates and Steven A. Cohen, has disclosed a 6.2% beneficial ownership stake in AngioDynamics Inc., totaling 2,559,389 shares.